Search results
Showing 801 to 850 of 1327 results for nice quality standards or clinical guidelines
Evidence-based recommendations on bortezomib (Velcade) for treating multiple myeloma before chemotherapy and stem cell transplant in adults.
UroShield for preventing catheter-associated urinary tract infections (HTG620)
Evidence-based recommendations on UroShield for preventing catheter-associated urinary tract infections.
Nasal Alar SpO2 sensor for monitoring oxygen saturation by pulse oximetry (MIB113)
NICE has developed a medtech innovation briefing (MIB) on the Nasal Alar SpO2 sensor for monitoring oxygen saturation by pulse oximetry .
NICE has developed a medtech innovation briefing (MIB) on Optilume for anterior urethral strictures .
Evidence-based recommendations on transperineal laser ablation for treating lower urinary tract symptoms of benign prostatic hyperplasia. This involves using laser energy to destroy some of the prostate tissue.
View recommendations for HTG737Show all sections
Evidence-based recommendations on continuous positive airway pressure for treating obstructive sleep apnoea/hypopnoea syndrome in adults.
icobrain ms for active relapsing–remitting multiple sclerosis (MIB291)
NICE has developed a medtech innovation briefing (MIB) on icobrain ms for active relapsing–remitting multiple sclerosis .
This indicator covers the percentage of patients with a diagnosis of heart failure after (start date) which has been confirmed by an echocardiogram or by specialist assessment between 3 months before or 3 months after entering on to the register. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM171
Evidence-based recommendations on procalcitonin testing for diagnosing and monitoring sepsis (ADVIA Centaur BRAHMS PCT assay, BRAHMS PCT Sensitive Kryptor assay, Elecsys BRAHMS PCT assay, LIAISON BRAHMS PCT assay and VIDAS BRAHMS PCT assay).
Evidence-based recommendations on apixaban (Eliquis) for treating and preventing recurrent deep vein thrombosis or pulmonary embolism in adults.
Remote ECG interpretation consultancy services for cardiovascular disease (MIB152)
NICE has developed a medtech innovation briefing (MIB) on remote ECG interpretation consultancy services for cardiovascular disease .
Find out more about the types of organisations that can register to be a stakeholder at NICE.
Find out more about the types of organisations that can register to be a stakeholder at NICE.
Mental wellbeing in over 65s: occupational therapy and physical activity interventions (PH16)
This guideline covers promoting mental wellbeing in people aged over 65. It focuses on practical support for everyday activities, based on occupational therapy principles and methods. This includes working with older people and their carers to agree what kind of support they need.
MammaTyper in vitro diagnostic test for determining breast cancer subtypes (MIB135)
NICE has developed a medtech innovation briefing (MIB) on the MammaTyper in vitro diagnostic test for determining breast cancer subtypes .
Woundchek Protease Status for assessing elevated protease status in chronic wounds (MIB83)
NICE has developed a medtech innovation briefing (MIB) on the Woundchek Protease Status for assessing elevated protease status in chronic wounds .
The STAK tool for preventing and treating knee stiffness (MIB252)
NICE has developed a medtech innovation briefing (MIB) on the STAK tool for preventing and treating knee stiffness .
This indicator covers the percentage of patients with moderate or severe frailty and/or multimorbidity who have received a medication review in the last 12 months which is structured, has considered the use of a recognised tool and taken place as a shared discussion. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM186
NICE has developed a medtech innovation briefing (MIB) on PromarkerD for predicting the risk of diabetic kidney disease in people with type 2 diabetes .
QuickChange Incontinence Wrap for urinary incontinence in men (MIB237)
NICE has developed a medtech innovation briefing (MIB) on QuickChange Incontinence Wrap for urinary incontinence in men .
Evidence-based recommendations on nivolumab–relatlimab (Opdualag) for untreated advanced (unresectable or metastatic) melanoma in people 12 years and over.
Summary of the evidence on alprostadil cream for treating erectile dysfunction to inform local NHS planning and decision-making
NICE has developed a medtech innovation briefing (MIB) on Paige Prostate for prostate cancer .
Evidence-based recommendations on nivolumab (Opdivo) with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma in adults.
Healthy.io test for home testing of urine albumin to creatinine ratio (MIB221)
NICE has developed a medtech innovation briefing (MIB) on Healthy.io test for home testing of urine albumin to creatinine ratio .
Alcohol interventions in secondary and further education (NG135)
This guideline covers interventions in secondary and further education to prevent and reduce alcohol use among children and young people aged 11 up to and including 18. It also covers people aged 11 to 25 with special educational needs or disabilities in full-time education. It will also be relevant to children aged 11 in year 6 of primary school.
CFHealthHub for managing cystic fibrosis during the COVID-19 pandemic (MIB219)
NICE has developed a medtech innovation briefing (MIB) on CFHealthHub for managing cystic fibrosis during the COVID-19 pandemic .
Degarelix for treating advanced hormone-dependent prostate cancer (TA404)
Evidence-based recommendations on degarelix (Firmagon) for advanced hormone-dependent prostate cancer in adults with spinal metastases.
Low dose rate brachytherapy for localised prostate cancer (HTG81)
Evidence-based recommendations on low dose rate brachytherapy for localised prostate cancer. This involves placing small radioactive seeds into the prostate that give off low doses of radiation to destroy cancer cells.
View recommendations for HTG81Show all sections
Sections for HTG81
Canagliflozin in combination therapy for treating type 2 diabetes (TA315)
Evidence-based recommendations on canagliflozin (Invokana) in combination therapy for treating type 2 diabetes in adults.
Sofosbuvir–velpatasvir for treating chronic hepatitis C (TA430)
Evidence-based recommendations on sofosbuvir–velpatasvir (Epclusa) for treating chronic hepatitis C in adults.
Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban (TA697)
Evidence-based recommendations on andexanet alfa (Ondexxya) for reversing anticoagulation form apixaban or rivaroxaban in adults with life-threatening or uncontrolled bleeding.
Evidence-based recommendations on percutaneous venoplasty for chronic cerebrospinal venous insufficiency in people with multiple sclerosis. This involves inserting an inflatable balloon into veins in the neck and chest in an attempt to widen them.
View recommendations for HTG501Show all sections
Bladder EpiCheck for detecting bladder cancer recurrence (MIB293)
NICE has developed a medtech innovation briefing (MIB) on Bladder EpiCheck for detecting bladder cancer recurrence .
NICE has developed a medtech innovation briefing (MIB) on SuperNO2VA for the relief of upper airway obstruction in people with obstructive sleep apnoea .
YOURmeds for medication support in long-term conditions (MIB289)
NICE has developed a medtech innovation briefing (MIB) on YOURmeds for medication support in long-term conditions .
Kendall DL for ECG monitoring in people having cardiac surgery (MIB177)
NICE has developed a medtech innovation briefing (MIB) on Kendall DL for ECG monitoring in people having cardiac surgery .
NICE has developed a medtech innovation briefing (MIB) on Lifelight First for monitoring vital signs .
Evidence-based recommendations on trastuzumab emtansine (Kadcyla) for human epidermal growth factor receptor 2 (HER2)-positive, unresectable, locally advanced or metastatic breast cancer in adults who have had trastuzumab and a taxane.
Caris Molecular Intelligence for guiding cancer treatment (MIB120)
NICE has developed a medtech innovation briefing (MIB) on Caris Molecular Intelligence for guiding cancer treatment .
AMBLor for identifying low-risk non-ulcerated early-stage cutaneous melanomas (MIB294)
NICE has developed a medtech innovation briefing (MIB) on AMBLor for identifying low-risk non-ulcerated early-stage cutaneous melanomas .
Using NICE content for AI purposes. Includes complete content, adaptation, contextualisation, translation, selected extracts and the use of our COVID-19 content internationally.
NICE has developed a medtech innovation briefing (MIB) on OxyMask for delivering oxygen therapy .
Evidence-based recommendations on high-intensity focused ultrasound for glaucoma in adults. This involves using high-intensity ultrasound to destroy a small amount of the tissue that makes fluid in the eye.
View recommendations for HTG527Show all sections
The Juxta CURES adjustable compression system for treating venous leg ulcers (MIB25)
NICE has developed a medtech innovation briefing (MIB) on the Juxta CURES adjustable compression system for treating venous leg ulcers
Ticagrelor for the treatment of acute coronary syndromes (TA236)
Evidence-based recommendations on ticagrelor (Brilique) for treating acute coronary syndromes in adults.
TYM smartphone otoscope for imaging and videoing the external ear canal and eardrum (MIB134)
NICE has developed a medtech innovation briefing (MIB) on the TYM smartphone otoscope for imaging and videoing the external ear canal and eardrum .
Evidence-based recommendations on reslizumab (Cinqaero) for treating severe eosinophilic asthma in adults.
Resources, case studies and patient decision aids to show how you can use evidence to improve care and services
Percutaneous deep venous arterialisation for chronic limb-threatening ischaemia (HTG698)
Evidence-based recommendations on percutaneous deep venous arterialisation for chronic limb-threatening ischaemia. This involves making a hole between a blocked artery and a vein, allowing the blood to flow into the leg beyond the blockage.
View recommendations for HTG698Show all sections